Clinical Trial Update: Randomized Double-Blind Placebo-Controlled Trial Using Recombinant Human Interleukin-10 for Moderate-to-Severe Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 for moderate-to-severe psoriasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• recombinant human interleukin-10 (interleukin-10)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Psoriasis | Phase 2 | Status: COMPLETED